Cargando…

Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial

Association with hypomethylating agents is a promising strategy to improve the efficacy of immune checkpoint inhibitors-based therapy. The NIBIT-M4 was a phase Ib, dose-escalation trial in patients with advanced melanoma of the hypomethylating agent guadecitabine combined with the anti-CTLA-4 antibo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noviello, Teresa Maria Rosaria, Di Giacomo, Anna Maria, Caruso, Francesca Pia, Covre, Alessia, Mortarini, Roberta, Scala, Giovanni, Costa, Maria Claudia, Coral, Sandra, Fridman, Wolf H., Sautès-Fridman, Catherine, Brich, Silvia, Pruneri, Giancarlo, Simonetti, Elena, Lofiego, Maria Fortunata, Tufano, Rossella, Bedognetti, Davide, Anichini, Andrea, Maio, Michele, Ceccarelli, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516894/ https://www.ncbi.nlm.nih.gov/pubmed/37739939 http://dx.doi.org/10.1038/s41467-023-40994-4

Ejemplares similares

Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
por: Chiarucci, Carla, et al.
Publicado: (2020)

Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy
por: Anichini, Andrea, et al.
Publicado: (2022)

A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation
por: Maio, Michele, et al.
Publicado: (2021)

Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
por: Maccalli, Cristina, et al.
Publicado: (2013)

Immunotherapy of brain metastases: breaking a “dogma”
por: Di Giacomo, Anna Maria, et al.
Publicado: (2019)

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
por: Calabrò, Luana, et al.
Publicado: (2021)

Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy
por: Lofiego, Maria Fortunata, et al.
Publicado: (2021)

The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward
por: Maio, Michele, et al.
Publicado: (2008)

Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
por: Fazio, Carolina, et al.
Publicado: (2018)

Tumor Immunology, toward a Success Story?
por: Sautès-Fridman, Catherine
Publicado: (2015)

Tumor microenvironment in NSCLC suppresses NK cells function
por: Cremer, Isabelle, et al.
Publicado: (2012)

A novel microRNA signature for the detection of melanoma by liquid biopsy
por: Sabato, Claudia, et al.
Publicado: (2022)

The European Academy of Tumor Immunology: Bridging fields, continents and generations
por: Kroemer, Guido, et al.
Publicado: (2012)

Characteristics of tertiary lymphoid structures in primary cancers
por: Goc, Jérémy, et al.
Publicado: (2013)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Complement System: Promoter or Suppressor of Cancer Progression?
por: Revel, Margot, et al.
Publicado: (2020)

Editorial: Tertiary Lymphoid Structures: From Basic Biology to Translational Impact in Cancer
por: Sautès-Fridman, Catherine, et al.
Publicado: (2022)

Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models
por: Galand, Claire, et al.
Publicado: (2012)

Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses
por: Goc, Jérémy, et al.
Publicado: (2014)

Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma
por: Petitprez, Florent, et al.
Publicado: (2021)

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2017)

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
por: Chung, Woonbok, et al.
Publicado: (2019)

Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer
por: Roosendaal, Jeroen, et al.
Publicado: (2019)

Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas
por: Darvishi, Emad, et al.
Publicado: (2020)

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
por: Wong, Jonathan, et al.
Publicado: (2022)

Trial watch: Chemotherapy with immunogenic cell death inducers
por: Vacchelli, Erika, et al.
Publicado: (2012)

Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum
por: Yagi, Hirokazu, et al.
Publicado: (2018)

Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine
por: Petitprez, Florent, et al.
Publicado: (2018)

Deep learning predicts short non-coding RNA functions from only raw sequence data
por: Noviello, Teresa Maria Rosaria, et al.
Publicado: (2020)

Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma
por: Minna, Emanuela, et al.
Publicado: (2020)

SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines
por: Di Giacomo, Anna M., et al.
Publicado: (2022)

Metastatic Melanomas Express Inhibitory Low Affinity Fc Gamma Receptor and Escape Humoral Immunity
por: Cohen-Solal, Joel F. G., et al.
Publicado: (2010)

Lung Tumor Microenvironment Induces Specific Gene Expression Signature in Intratumoral NK Cells
por: Gillard-Bocquet, Mélanie, et al.
Publicado: (2013)

Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention
por: Sautès-Fridman, Catherine, et al.
Publicado: (2016)

B cells and cancer: To B or not to B?
por: Fridman, Wolf Herman, et al.
Publicado: (2020)

Cancer bio-immunotherapy XVIII annual NIBIT-(Italian network for tumor biotherapy) meeting, October 15–16, 2020
por: Bellone, Matteo, et al.
Publicado: (2022)

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer
por: Albany, Costantine, et al.
Publicado: (2020)

Th17 Cells Are Involved in the Local Control of Tumor Progression in Primary Intraocular Lymphoma
por: Galand, Claire, et al.
Publicado: (2011)

Trial Watch: Adoptive cell transfer immunotherapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy
por: Galluzzi, Lorenzo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sohnsqc3uj98a0oib7g1hbi183